论文部分内容阅读
目的 探讨西黄胶囊与细胞免疫联合治疗对晚期癌症患者止痛效果,并分析其不良反应,以指导临床合理用药.方法 将本院2013年3月~2015年1月期间收治的200名晚期癌症患者作为研究对象,根据不同的方法分为 A、B、C、D 四组,每组患者50例.A 组患者单纯采用西黄胶囊治疗, B组患者单纯采用DC-CIK细胞免疫治疗,C组患者采用西黄胶囊联合 DC -CIK 细胞免疫治疗,D 组患者采用西黄胶囊联合CIK细胞免疫治疗.记录四组的治疗效果.结果 采用西黄胶囊联合细胞免疫疗法的C组患者总有效率为90%,明显高于A (50%)、B (58%)、D (74%) 三组.比较差异有统计学意义(P<0.01).C组患者不良反应发生率为10%,明显低于A (30%)、B (24%)、D (18%) 三组,利用DC-CIK细胞免疫疗法患者有轻微发热症状,但在恰当护理下能及时好转.差异有统计学意义 (P <0.01).结论 对临床癌症晚期患者采用西黄胶囊联合细胞生物治疗能够有效缓解患者疼痛,减少不良反应,改善患者临床状况和生活质量,值得在临床推广应用.“,”Objective To explore the effects and adverse reactions of Xihuang capsules combined with cell immunity in the treatment of the pain in the patients with advanced cancer. Methods 200 Patients with advanced cancer treated in our hospital from March in 2013 to January in 2015 were enrolled. They were divided into A, B, C and D groups, each of the groups had 50 patients. Group A only reccived xihuang capsules. Group B only received DC-CIK cell immunotherapy. Group C received Xihuang capsules combined with DC-CIK cell immunotherapy. Group D received Xihuang capsules combined with CIK cell immunotherapy. The thera-peutic effects of all the patients were recored. Results The total effective rate in group C was 90%, which was significantly higher than that in group A (50%), group B(58%) and group D(74%). There was statistically significant difference(P<0.01). The incidence of adverse reactions in group C was 10%, which was significantly lower than that in group A(30%), group B(24%) and group D (18%). The patients who received DC-CIK cell immunotherapy had mild fever, but they improved after the appropriate care timely. There was statistically significant difference (P<0.01). Conclusion Xihuang capsules combined with DC-CIK can relieve the pain effectively, reduce the adverse reactions and improve the quality life of the patients with advance cancer.